Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer’s disease assessment

Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer’s disease assessment

IntroductionPlasma Aβ42/40 ratio can help predict amyloid PET status, but its clinical utility in Alzheimer’s disease (AD) assessment is unclear.MethodsAβ42/40 ratio was measured by LC-MS/MS for 250 specimens with associated amyloid PET imaging, diagnosis, and demographic data, and for 6,192 consecu...

Full description

Bibliographic Details
Main Authors: Darren M. Weber, Steven W. Taylor, Robert J. Lagier, Jueun C. Kim, Scott M. Goldman, Nigel J. Clarke, David E. Vaillancourt, Ranjan Duara, Karen N. McFarland, Wei-en Wang, Todd E. Golde, Michael K. Racke
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Neurology
Subjects:
Alzheimer’s disease
beta-amyloid
blood biomarkers
LC-MS/MS
PET
prescreening
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2024.1364658/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2024.1364658/full

Similar Items